02185.HK
Shanghai Bio-heart Biological Technology Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 0.93
−3.63%Year over year
Reported trailing growth
- Revenue
- +81.4%
- EBITDA
- -59.3%
- EBIT
- -62.2%
- EPS
- +16.2%
- Free cash flow
- +14.9%
- Operating cash flow
- -0.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +1.4%
- EBIT
- -14.4%
- Net income
- +22.4%
- EPS
- +22.2%
- Free cash flow
- +56.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026